Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this clinical investigation is to determine the safety and feasibility of detecting acoustic signals related to blood supply in subjects with acute large vessel occlusion (LVO) stroke by using the SONAS® device.
This clinical investigation will assess the performance of the SONAS® device in subjects with acute stroke admitted to the emergency department or stroke unit within 24 hours of symptoms onset and confirmed occlusion of either the proximal middle, distal M1-segment cerebral arteries, or distal internal carotid arteries (including carotid-T occlusion) by cerebral magnetic resonance imaging (cMRI) or cerebral imaging computed tomography (cCT), including perfusion weighted (pw) imaging sequences, will be considered for the investigation.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Experimental:Diagnostic | Experimental | Diagnostic Test: SONAS® Ultrasound Device |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| SONAS® Ultrasound Device | Device | The SONAS® Ultrasound Device is intended for non-invasive transcranial ultrasound and used with a commercially approved contrast agent (e.g., Lumason®/SonoVue®). |
| Measure | Description | Time Frame |
|---|---|---|
| Assessment of Brain Perfusion | Measurement of the kinetic parameter time to peak (TTP) in the right and left-brain hemisphere during the SONAS® test | 24 hours |
| Comparison | Comparison between SONAS® versus cMRI or cCT generated intra-individual differences in the parameter TTP in the right and left-brain hemisphere | 7 days |
| Assessment of Adverse Events | Frequency, severity, relationship (to device, contrast agent, or procedure), and outcome of AEs Frequency, severity, relationship (to device, contrast agent, or procedure), and outcome of AEs Frequency, severity, relationship (to device, contrast agent, or procedure), and outcome of AEs | 72 hours |
Not provided
Not provided
Inclusion Criteria:
Written informed consent obtained
Male or female subject ≥18 years
Clinical diagnosis of acute stroke (NIHSS score: ≥10)
Time of stroke symptoms onset: ≤24 hours
Confirmed occlusion of either the proximal middle cerebral artery (occlusion of the proximal, middle or distal M1-segment) or the distal internal carotid artery (including carotid-T occlusion) by cMRI or cCT (including perfusion weighted imaging sequences)
Women of childbearing potential must have a negative urine or serum beta human chorionic gonadotropin result, obtained within 24 hours before administration of SonoVue®
Women of non-childbearing potential can be included in the clinical investigation, if confirmed by fulfilling at least 1 of the following criteria:
Exclusion Criteria:
Subjects with known contraindications to the use of SonoVue®:
Subjects known to have right-to-left shunts, severe pulmonary hypertension (pulmonary artery pressure >90 mmHg), uncontrolled systemic hypertension, and subjects with acute respiratory distress syndrome
SonoVue® must not be used in combination with dobutamine in subjects with conditions suggesting cardiovascular instability where dobutamine is contraindicated
Known hypersensitivity to any of the following substances:
Pregnant women
Subjects with severe cardiac or pulmonary disease as defined by the treating physician
Subjects with acute endocarditis and/or artificial heart valve
Subjects with acute systemic inflammation and/or sepsis
Subjects with hyperactive coagulation states and/or a recent thromboembolism
Subjects with end stage renal or hepatic disease
Subjects with known metal skull implants in the anatomical area of the temporal/parietal bones, or with anatomical formation of the head or ear that may interfere with proper headset placement, or with significant observable asymmetry in head formation
Subjects with known implanted deep brain stimulation devices
Subjects with known or suspected fracture(s) of the temporal/parietal skull bones, or with open skin injuries in the anatomical area of the temporal/parietal lobes
Subjects with known significant blood loss prior to or during the test procedure, SONAS® should not be used unless the blood pressure of the subject is verified to be stabilized
Subjects with axial (coronal) skull diameters of <12 cm or >18 cm
Subjects participating in another clinical investigation with an investigational drug or device within 3 months of enrollment or planned participation at any time during this clinical investigation
Previous participation in this clinical investigation
Employees of the clinical investigation site or the sponsor directly involved with the conduct of the clinical investigation, or immediate family members of any such individuals
Subjects committed to an institution by an order issued either by the courts or by an authority
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Andreas Cischek | Contact | +49 89 893 1190 | andreas.cischek@fgk-cro.com | |
| Thilo Hoelscher, MD | Contact | 619-277-3702 | thilo@burlconcepts.com |
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Universitätsklinik für Neurologie / Medizinische Universität Wien | Not yet recruiting | Vienna | 1090 | Austria |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D020521 | Stroke |
| ID | Term |
|---|---|
| D002561 | Cerebrovascular Disorders |
| D001927 | Brain Diseases |
| D002493 | Central Nervous System Diseases |
| D009422 | Nervous System Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Universitätsklinik für Neurologie / Universitätsklinikum Regensburg | Recruiting | Regensburg | 93053 | Germany |
|
| D014652 | Vascular Diseases |
| D002318 | Cardiovascular Diseases |